CCR2 antagonists such as PF-04136309 have been shown to reduce tumor-associated macrophage infiltration and enhance antitumor immunity in pancreatic ductal adenocarcinoma, leading to improved tumor control in combination with chemotherapy [53]. This evidence concerns the gene CCR2 and neoplasm.